Dockery LE, Rubenstein AR, Ding K, et al. - In this multi-institutional retrospective review, researchers investigated how 2nd line treatment with non-platinum or targeted therapy influences epithelial ovarian cancer (EOC) patients recurring 6–12 months after completion of primary platinum-based chemotherapy. Participants were 177 patients with recurrent EOC and platinum-free interval (PFI) of 6–12 months after primary chemotherapy. Comparisons were performed for platinum vs non-platinum chemotherapy or targeted therapy for 2nd line therapy. Most of the participants were Caucasian, had serous histology, and had undergone primary cytoreductive surgery. In 28% of patients, the omission of 2nd line platinum was documented. In 16% of patients, 2nd line treatment with bevacizumab was administered, and 19% received other targeted therapies. In this study, worse survival was reported in correlation with the use of non-platinum chemotherapy and even targeted therapy to prolong PFI in patients with EOC recurring between 6 and 12 months.